Patent: 9,504,603
✉ Email this page to a colleague
Summary for Patent: 9,504,603
| Title: | Intraocular delivery devices and methods therefor |
| Abstract: | Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on the injector device, or on a portion of the injection device housing, or on a drug reservoir. Some devices may be removably attached to a drug reservoir, for example, through a luer connector. Other devices may comprise internal luer seal for securely connecting a drug conduit of the device to the luer cavity of a drug reservoir. Yet other devices may comprise a priming-enabling element to facilitate the drug priming of a shielded needle. Related methods and systems comprising the devices are also described. |
| Inventor(s): | Lerner; Leonid E. (Corona Del Mar, CA) |
| Assignee: | OcuJect, LLC (Newport Beach, CA) |
| Application Number: | 14/047,476 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,504,603
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2032-04-02 |
| Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2032-04-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
